It is made available under a CC-BY-NC-ND 4.0 International license .

High prevalence of olfactory disorders 18 months after contracting COVID-19: a case-control study

*Johannes Frasnelli^{1, 2}, *Arnaud Tognetti¹, Evelina Thunell¹, Anja L. Winter¹, Mats J. Olsson¹, Nina Greilert³, Jonas K. Olofsson⁴, Sebastian Havervall³, *Charlotte Thålin³, and *Johan N. Lundström^{1, 5}

¹ Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

² Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivieres, QC, Canada

³ Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden

⁴ Department of Psychology, Stockholm University, Stockholm, Sweden

⁴ Monell Chemical Senses Center, Philadelphia, PA, USA

* contributed equally to this manuscript

Total words: 3320 Total Figures: 2

Communicating Author: Johan Lundström, PhD Dept. of Clinical Neuroscience Karolinska Institutet Nobels väg 9 17177 Stockholm, Sweden

E-mail: Johan.Lundstrom@ki.se

It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background: More than a year after recovering from COVID-19, a large proportion of individuals still report olfactory dysfunctions. However, olfactory dysfunction was common also before the COVID-19 pandemic. To establish the prevalence of olfactory dysfunction while controlling for existing cases, we tested individuals with established COVID-19 in the first wave of the pandemic using psychophysical testing of smell functions.

Methods: Participants were regularly tested for SARS-CoV-2 IgG antibodies since the start of the pandemic. To assess normal rate of dysfunction in the population and skewed recruitment of individuals with prior olfactory dysfunction, SARS-CoV-2 IgG naïve individuals were tested as a control group.

Results: One and a half years after COVID-19, 37% of individuals who recovered from COVID-19 demonstrated a clinical reduction in their sense of smell, compared to only 20% of the control group. Critically, 51% of COVID-19-recovered individuals reported parosmia symptoms, compared to only 5% in the control group.

Conclusions: In summary, a full 65% of individuals who recovered from COVID-19 experienced some form of olfactory dysfunction 18 months later. This means that the first wave of COVID-19 increased the prevalence of a clinical reduction in the sense of smell in the population with 17 percentage points and the prevalence of any form of olfactory dysfunction with a staggering 41 percentage points when compared to individuals not infected by the virus. Given the amount of time since the initial insult to the olfactory system, it is likely that these olfactory problems are permanent in a plurality of patients.

Keywords: Olfactory dysfunction; Prevalence; Parosmia

It is made available under a CC-BY-NC-ND 4.0 International license .

Olfactory dysfunction is the most specific symptom of acute COVID-19 (Gerkin et al., 2021; Rudberg et al., 2020) and smell abilities are heavily impacted by COVID-19 (Parma et al., 2020). Olfactory function recovers in many patients after olfactory dysfunction in the acute phase of COVID-19 (Bussiere et al., 2022). However, a non-negligeable proportion of patients exhibits chronic olfactory dysfunction after COVID-19 (McWilliams et al., 2022). Estimations of the prevalence of olfactory dysfunction more than 6 months after an infection by SARS-CoV-2 – a threshold for chronicity of olfactory dysfunction – vary widely (Boscolo-Rizzo et al., 2022; Bussiere et al., 2021; Bussiere et al., 2022; Capelli & Gatti, 2021; Hopkins et al., 2021; Lechien et al., 2021; Ohla et al., 2022). Critically, a recent assessment of olfactory dysfunction based on subjective reports only, suggests that two years after contracting COVID-19, a staggering 61% still experience olfactory dysfunction (McWilliams et al., 2022).

Although it has been clearly demonstrated that COVID-19 results in long-term olfactory dysfunction, the estimations of the prevalence of olfactory dysfunction due to COVID-19 suffer from several caveats. First, most of the estimations were based on self-report only; selfassessment of olfactory dysfunctions is, however, unreliable (Landis et al., 2003; Lotsch & Hummel, 2019). Second, COVID-19 status was seldom determined by biological assays and most often based on self-reported COVID-19 status which could have biased the estimations. Third, the prevalence of olfactory dysfunction due to other causes than COVID-19 was not considered. It is crucial to compare the prevalence numbers to the background of existing olfactory dysfunction in the tested population, preferably in COVID-19-naïve individuals, given how common olfactory dysfunction was even before the pandemic. In fact, the prevalence of olfactory dysfunction before the pandemic was estimated to be around 20% (Bramerson et al., 2004; Devanand et al., 2015; Karpa et al., 2010; Landis et al., 2004) with leading causes being sinonasal disease, traumatic brain injury, and viral infection of the upper respiratory tract (Damm et al., 2004; Hummel et al., 2017); the causing virus remained unknown in nearly all cases (Konstantinidis et al., 2006). Thus, if one wants to know the true prevalence of olfactory dysfunction after COVID-19, one must also consider the existing prevalence of olfactory dysfunction due to other causes in a subsample where COVID-19 avoidance is established.

The term *olfactory dysfunction* describes different insults to the sense of smell. A general subdivision distinguishes (a) *qualitative olfactory dysfunction* – describing altered perception of odors; this includes the perception of odors as different (parosmia) or the perception of odors in the absence of an odor source (phantosmia) – and (b) *quantitative olfactory dysfunction* – describing reduction (hyposmia) or loss (anosmia) of olfactory function (Hummel et al., 2017). These dysfunctions can be measured using different methods. In respect of qualitative olfactory

It is made available under a CC-BY-NC-ND 4.0 International license .

dysfunction, standardized assessment of parosmia or phantosmia can currently only be carried out with questionnaires (Landis et al., 2010) given its characterization as change of subjective experiences. Regarding assessments of quantitative olfactory dysfunction, one widespread approach is the use of questionnaires with self-evaluation. However, the self-evaluation of olfactory function is notoriously inexact (Landis et al., 2003; Lotsch & Hummel, 2019); therefore, resulting numbers are to be taken cautiously. The gold standard to assess quantitative olfactory dysfunction is therefore to use psychophysical tests (Doty et al., 1984; Hummel et al., 1997). When aiming to estimate the true prevalence of olfactory dysfunction after COVID-19, one should therefore aim to assess olfactory function with well-validated psychophysical measures and questionnaires.

We designed this study to overcome these two major highlighted issues by assessing olfactory function in participants where continuous serum assessments were available to establish infection with SARS-CoV-2. Specifically, we included two groups of participants, namely (a) one group who had serologically confirmed COVID-19 during the observation period, and (b) a control group for whom we could exclude any infection with SARS-CoV-2 due to continuous serum testing. Our objective was to evaluate olfactory function with validated olfactory tests in both groups to establish the prevalence of olfactory dysfunction due to COVID-19 up to 18 months after infection. We hypothesized that infection with SARS-CoV-2 is associated with a prevalence of olfactory dysfunction that is significantly higher than in those without infection.

Methods

Participants

All participants originated from the COMMUNITY (COVID-19 Immunity) study which enrolled 2149 healthcare workers at Danderyd Hospital, Stockholm in April 2020. All participants were tested for SARS-CoV-2 IgG antibodies every four months, i.e. since the start of the pandemic in Sweden (Rudberg et al., 2020) (see https://ki.se/en/kids/community for more information). We screened out individuals with acute nasal congestion/rhinorrhea, neurodegenerative diseases, and other conditions associated with reduced olfactory function. All participants gave written informed consent, and the study was approved by the Swedish Ethical Review Authority (Dnr 2021-02052).

We recruited predominantly healthcare workers that had COVID-19 in the first wave in Stockholm during spring 2020, between January and May 2020. From a total of 320 SARS-CoV-2 IgG positive individuals (COVID+; average time since seroconversion 447, SD ±73, days), 100 volunteered, with two exclusions (due to an inability to perform the tests), leaving a final sample

It is made available under a CC-BY-NC-ND 4.0 International license .

of 98 COVID+ participants (mean age: 48 years; SD \pm 12; 84 women). All participants had experienced mild COVID-19, which was defined as a COVID-19 illness that did not require hospitalization. We further invited an equal number of SARS-CoV-2 naïve (COVID-), i.e., SARS-CoV-2 IgG negative at all sampling time points since enrolment at the onset of the SARS-CoV-2 pandemic in Sweden, healthcare workers from the same cohort, with a similar age profile. A total of 44 individuals were included with 3 individuals subsequently excluded (due to olfactory-related sickness, excessive construction noise during testing precluding concentration, and refusal to perform some tests). This resulted in a final COVID- sample of 41 (mean age: 51 years; SD \pm 11; 38 women).

Chemosensory assessments

<u>Qualitative</u> olfactory dysfunction was assessed using a questionnaire containing four items (Landis et al., 2010). The questionnaire addresses aspects of qualitative olfactory dysfunction with regards to alterations in food perception, the presence of odors despite the absence of an odor source, pleasantness of perceived odors, and the impact of the perception of altered odors; participants can respond on a 4-point scale (ranging from *never* to *always*). We analyzed the questionnaire in two ways: first, we calculated the sum score of all four items (Parosmia score). Then, we counted the number of participants who responded *always*, *often*, or *rarely* to the question *The biggest problem is not that I do not or weakly perceive odors, but that they smell different than they should* vs those who responded *never* (Parosmia presence).

<u>Quantitative</u> olfactory dysfunction was assessed with two different approaches. First, we assessed subjective olfactory function by using a 10-point visual analog scale. Participants responded to the question "*How has your sense of smell been during the last three days?*", responses ranged from 0 (no smell) to 10 (very good sense of smell). Second, we assessed olfactory function psychophysically using the Sniffin' Sticks test battery (Hummel et al., 1997). This test is based on felt-tip pen-like odor dispensing devices and allows for the separate assessment of the ability to discriminate (D) and identify (I) odors as well as an olfactory detection threshold (T). To assess odor quality discrimination, we presented 16 triplets of pens were presented to the participant. Each triplet consisted of two pens with identical odorants and one with an odorant of different quality. To evaluate odor identification abilities, we used a forced-choice cued identification task using 16 different odorants. Each odor was presented together with a cue card listing four alternative odor. To estimate odor detection thresholds, we used the odor n-Butanol in a three-alternative forced-choice staircase procedure with seven reversals in a 16-step binary dilution series. The individual sub-scores were then combined to a global TDI score, for which

Page 4/3

It is made available under a CC-BY-NC-ND 4.0 International license .

normative data are available and which allows for the diagnosis of normosmia, hyposmia, and functional anosmia (Oleszkiewicz et al., 2019).

Serological analyses of antibodies

A detailed description of serological analyses can be found in (Rudberg et al., 2020). Briefly, IgG reactivity was measured towards three different SARS-CoV-2 virus protein variants, Spike trimers, Spike S1 domain, and Nucleocapsid protein, and analyzed using a multiplex antigen bead array in high throughput 384-plates form at using a FlexMap3D (Luminex Corp) (Pin et al., 2019). To be assigned as a SARS-CoV-2 IgG positive sample, reactivity against at least two of the three different variants of the viral antigens was required, calculated to have 99.2% sensitivity and 99.8% specificity (Rudberg et al., 2020). We did not determine individual virus variants but random sampling of the Stockholm population during the time participants in this study were infected showed that three main strains of Variants Being Monitored (VBM) of the SARS-CoV-2 dominated, namely the Wildtype, and to a lesser extent, the B.1.1/B.1.1.29 and B.1.1.1/C.14 (Drydak & Albert, 2021).

Procedure

Chemosensory data were collected between June and November 2021. Upon inclusion, participants responded to a questionnaire containing the VAS and the parosmia questionnaire before the Sniffin' Sticks test battery was administered. The total testing time was 1.5h, and participants received a monetary compensation for their participation.

Statistics

To assess whether an infection with SARS-CoV-2 leads to long-term qualitative and quantitative olfactory dysfunctions we compared the (a) parosmia questionnaire score (4 COVID+ and 3 COVID- individuals refrained from answering this questionnaire), (b) subjective olfactory dysfunction, and (c) Sniffin' Sticks test score between infected individuals a year and a half after recovering from COVID-19 (COVID+) and COVID-19 naïve individuals (COVID-). To correct for the uneven sample size between the two groups and to control for the non-normal distributions of the variables, we performed non-parametric statistical group comparisons using a two-sided Wilcoxon rank sum test with continuity correction. We also compared frequencies between groups using chi-square tests.

It is made available under a CC-BY-NC-ND 4.0 International license .

Availability of data materials

The datasets generated and associated data scripts to generate results and figures are available on the Open Science Framework data depository

https://osf.io/hja2p/?view_only=53d8bb21c06c48d2bee231f75797789c

Results

We first assessed how strongly individuals in respective group experienced <u>qualitative</u> olfactory dysfunction 18 months after the initial COVID-19 wave in Sweden with the Landis 4-question parosmia scale. The score was significantly higher in the COVID+ group, 2.8 points ($SD \pm 2.8$), than in the COVID- group, 0.7 points ($SD \pm 1.2$; Wilcoxon rank sum, W = 2595; N = 132, p < .0001; Figure 1A). Accordingly, we found that there were significantly more individuals from the COVID+ group reporting parosmia (48 of 94 participants - 51%) relative to individuals from the COVID-group (2 of 38 participants - 5%; X^2 (1, N = 132) = 22.2, p < .0001). To understand the degree of symptom severity, we assessed each group answers to the severity question. As can be seen in Figure 1B, slightly more than half of the individuals in the COVID+ group who reported parosmia symptoms experienced only minor symptoms (None 49%, Mild, 28%, Medium 16%, Severe 7%). This means that about a quarter of all individuals in the COVID+ group experience medium to severe parosmia symptoms 18 months after their COVID-19 diagnose.




Figure 1. Distribution of parosmia score. A) Distribution of scores per patient group (N = 94), COVID-19 positive (COVID+) and COVID-19 naïve (COVID-, N = 38), on the Landis parosmia questionnaire. **B**) Proportion of individuals in each patient group, grouped according to reported parosmia severity score.

It is made available under a CC-BY-NC-ND 4.0 International license .

Next, we assessed <u>quantitative</u> olfactory dysfunction. First, we explored potential differences in subjective performance: here, participants from the COVID+ group (N = 98) evaluated their olfactory function as significantly worse, 6.9 ($SD \pm 2.5$) out of a total of 10 points, than the COVID- group (N = 41), 8.9 points ($SD \pm 1.2$; W = 955; N = 139, p < .0001). In line with their subjective experience, their average Sniffin' Sticks TDI score was significantly lower according to a Wilcoxon rank sum test in the COVID+ group, 30.9 points ($SD \pm 5.9$), compared to the COVID- group, 34.0 points ($SD \pm 3.4$; W = 1416.5; N = 139, p = .006; Figure 2A).




Figure 2. A) Mean TDI scores for the COVID-19 positive (COVID+, N = 98) and COVID-19 naïve (COVID-, N = 41) groups showed as bars with error bars denoting standard deviation (SD) as well as values for each participant indicated by circles. Dashed lines indicate cut-off scores for the clinical diagnoses Hyposmia and Anosmia. Higher TDI scores (possible range 1-48) indicate better olfactory performance. **B**) Proportion of COVID+ participants (N = 94) in each olfactory dysfunction classification group.

Finally, we assessed the proportion of individuals with a clinical olfactory dysfunction 18 months after the first COVID-19 wave. Based on the Sniffin'Sticks score, the frequency of quantitative olfactory dysfunction was significantly higher (X^2 (1, N = 139) = 6.28, p = .01) in the COVID+ group than in the COVID- group. In fact, in the COVID+ group, 37% had a quantitative olfactory dysfunction with 4 exhibiting anosmia and 32 exhibiting hyposmia. In the control group, 20% had a quantitative olfactory dysfunction, all of which exhibited hyposmia.

Moreover, as to be expected, there was a considerable comorbidity between diagnoses. In the COVID+ group (N = 94), while 35% experienced no olfactory dysfunction at all, 14% experienced anosmia/hyposmia but no parosmia, 29% experienced parosmia but no anosmia/hyposmia, and 22% experienced both anosmia/hyposmia and parosmia. In other words,

It is made available under a CC-BY-NC-ND 4.0 International license .

a total of 65% of tested COVID+ participants experienced some form of olfactory dysfunction on average 18 months after experiencing COVID-19 (Figure 2B). This frequency was lower in the COVID- group (N = 38) where only 24% experienced some form of olfactory dysfunction (76% experienced no olfactory dysfunction, none had anosmia, 18% experienced hyposmia but no parosmia, 3% experienced parosmia but no hyposmia, and 3% experienced both hyposmia and parosmia). As expected, the frequency of combined quantitative and qualitative olfactory dysfunction was significantly lower in the COVID- group compared to the COVID+ group (X^2 (1, N = 132) = 32.4, *p* < .0001).

Discussion

A year and a half after recovering from COVID-19, more than half (65%) of all participants still exhibited some form of olfactory dysfunction with more than a third (37%) of all showing a clinically reduced sense of smell. In comparison, approximately a quarter (24%) of individuals without prior SARS-CoV-2 infection displayed clinically altered sense of smell. Further, amongst COVID-19 survivors, about half (51%) experienced parosmia, but only 5% in the SARS-CoV-2 naive group; an increase of parosmia due to COVID-19 with 46 percentage points. More specifically, the first wave of COVID-19 nearly doubled the prevalence of a clinical reduction in odor sensitivity in the population from 20% to 36% and increased the prevalence of any form of olfactory dysfunction by a full 41 percentage points compared to individuals whose immune system was never exposed to the virus.

Olfactory dysfunction is common in the general population. Before the COVID-19 pandemic, the rate of quantitative olfactory dysfunction was consistently estimated in the range of 20% (Bramerson et al., 2004; Landis et al., 2004). In our control sample of COVID-19 naïve individuals, we found a strikingly similar percentage with 20% of the participants exhibiting quantitative olfactory dysfunction. As outlined above, olfactory dysfunction can have different etiologies, including sinonasal disease, traumatic brain injury, neurodegenerative diseases, and others (Damm et al., 2004; Hummel et al., 2017). It is therefore crucial to assess the prevalence of olfactory dysfunction due to COVID-19 against this background of olfactory dysfunction in the population. Our data suggests that COVID-19 roughly doubles the prevalence of quantitative olfactory dysfunction in the general population. A different and bleaker picture emerges when looking at qualitative olfactory dysfunction, i.e., parosmia and phantosmia. They are relatively rare in the general population, which is also reflected by the prevalence of 5% in the control group that align with past assessments of Swedish samples (Nordin et al., 2007; Olofsson et al., 2022).

It is made available under a CC-BY-NC-ND 4.0 International license .

However, nearly half of the COVID+ group exhibited qualitative olfactory dysfunction on average 18 months after contracting COVID-19.

It is not yet completely understood how an infection with SARS-CoV-2 leads to olfactory dysfunction. The leading explanation how SARS-CoV-2 causes acute olfactory dysfunction in COVID-19 is linked to the virus' ability to infect human cells co-expressing ACE2 and TMPRSS2 proteins, which is the case for sustentacular cells in the olfactory mucosa (Cooper et al., 2020). Upon infection, these cells degenerate which disturbs the local environment which, crucially, results in cell death of olfactory receptor neurons and associated olfactory dysfunction (Cooper et al., 2020; Xydakis et al., 2021). The olfactory system demonstrates, however, a very good ability to regenerate (Reden et al., 2006) which might explain why most of SARS-CoV-2 infected individuals regain olfactory abilities within weeks following the acute phase (Bussiere et al., 2021; Bussiere et al., 2022). It is not yet clear why some individuals do not completely regain their olfactory abilities.

Recent data from the verbal track-and-trace program in the United Kingdom suggests that fewer individuals report subjective olfactory dysfunction after infection with the later Omicron (BA.1. and BA.2) variants than the original virus variants (Vihta et al., 2022). We do not know what specific virus variant individuals in our sample was infected by. It is further not possible to know exactly what proportions of virus variants dominated in our specific sample but random sampling of the Stockholm population at the time indicated that the Wildtype and, to a lesser extent, the B.1.1/B.1.1.29 and B.1.1.1/C.14 strains dominated (Drydak & Albert, 2021). Although tentative data do suggest that fewer individuals report subjective olfactory dysfunction after Omicron variant infection, these are based on subjective data that are collected a day or two after a positive test. Whether potential lower numbers of olfactory dysfunction which in turn might affect long-term outcomes, remain to be determined. Future studies should address whether other virus variants will be as detrimental to olfactory functions as in our present study.

A significant strength of the present study is that all participants were continuously serologically monitored from the onset of the pandemic meaning that it can be firmly established that all participants in the COVID+ group had gone through a COVID-19 infection and at what point in time. Critically, we can firmly claim that no participants in the COVID- group, a control group from the same cohort, had seroconverted at any point before sensory testing, thereby giving us a true baseline for existing olfactory dysfunction prevalence. Likewise, most studies assessing olfactory dysfunction in a general population suffer from collider bias, i.e., that individuals that experience olfactory problems are more likely to volunteer for the study in the first place, thereby

It is made available under a CC-BY-NC-ND 4.0 International license .

erroneously increasing the prevalence of dysfunction. By using a control group undergoing the same recruitment strategy as the target group and the population being healthcare professionals, likely better informed and willing to participate in research without personal gain, it can be assumed that collider bias acts in equal strength across groups. The fact that we obtained identical prevalence of olfactory dysfunction in the control group as the only two previously published prevalence studies in a Swedish sample supports this notion (Nordin et al., 2007; Olofsson et a., 2022). However, these strengths come from the fact that we sampled from a smaller group of closely monitored individuals with a profession that is unfortunately highly taxed for time during a pandemic. This meant that obtaining data from a large and diverse sample was not possible. Another weakness is that the sex ratio in both groups were skewed with more women participating, but potentially reflecting the underlying population. Women are known to be slightly more prone to experience long-term effects to their olfactory functions after upper airway infections (Seiden, 2004). Whether our sample's skewed sex ratio affects the generalization of our results is not known.

In conclusion, we show that COVID-19 nearly doubles the already large prevalence of quantitative olfactory dysfunction to approximately 37%. Furthermore, about half of the COVID-19 survivors exhibit qualitative olfactory dysfunction. Finally, nearly two thirds of COVID-19 survivors exhibit olfactory dysfunction of some form 18 months after the infection; given the length of time, it is likely that these olfactory problems are permanent in a plurality of patients. Clinicians of all fields will face many of these patients, who need appropriate counseling and guidance.

AUTHORSHIP CONTRIBUTION

ALW, NG, ET, SH, CT, JKO, & JNL contributed to design and acquisition, JF, AT, & JNL analysed and wrote the manuscript, all authors contributed to the interpretation of the data, revisions of the manuscript, and provided final approval of the article before submission.

CONFLICT OF INTEREST

No conflicts of interest are reported for all authors.

FUNDING

Funding was provided by grants awarded to JNL and CT from the Knut and Alice Wallenberg Foundation (KAW 2018.0152 and KAW 2020.0182, respectively), the Swedish Research Council

Page 10/3

It is made available under a CC-BY-NC-ND 4.0 International license .

(2021-06527) and a donation from Stiftelsen Bygg-Göta för Vetenskaplig forskning to JNL, as well as the Swedish Heart Lung Foundation to CT.

References

Boscolo-Rizzo, P., Guida, F., Polesel, J., Marcuzzo, A. V., Antonucci, P., Capriotti, V., Sacchet, E., Cragnolini, F., D'Alessandro, A., Zanelli, E., Marzolino, R., Lazzarin, C., Tofanelli, M., Gardenal, N., Borsetto, D., Hopkins, C., Vaira, L. A., & Tirelli, G. (2022). Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study. *Eur Arch Otorhinolaryngol*, *279*(1), 515-520. <u>https://doi.org/10.1007/s00405-021-06839-w</u>

Bramerson, A., Johansson, L., Ek, L., Nordin, S., & Bende, M. (2004). Prevalence of olfactory dysfunction: the skovde population-based study. *Laryngoscope*, *114*(4), 733-737. <u>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15064632</u>

Bussiere, N., Mei, J., Levesque-Boissonneault, C., Blais, M., Carazo, S., Gros-Louis, F., De Serres, G., Dupre, N., & Frasnelli, J. (2021). Chemosensory Dysfunctions Induced by COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare Workers. *Chem Senses*, *46.* <u>https://doi.org/10.1093/chemse/bjab038</u>

Bussiere, N., Mei, J., Levesque-Boissonneault, C., Blais, M., Carazo, S., Gros-Louis, F., Laforce, R., De Serres, G., Dupre, N., & Frasnelli, J. (2022). Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up. *Chem Senses*, *47*. <u>https://doi.org/10.1093/chemse/bjac010</u>

Capelli, M., & Gatti, P. (2021). Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional recovery after eight months. *J Laryngol Otol*, *135*(3), 224-228. <u>https://doi.org/10.1017/s0022215121000670</u>

Cooper, K. W., Brann, D. H., Farruggia, M. C., Bhutani, S., Pellegrino, R., Tsukahara, T., Weinreb, C., Joseph, P. V., Larson, E. D., Parma, V., Albers, M. W., Barlow, L. A., Datta, S. R., & Di Pizio, A. (2020). COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. *Neuron*, *107*(2), 219-233. <u>https://doi.org/10.1016/j.neuron.2020.06.032</u>

Damm, M., Temmel, A., Welge-Lussen, A., Eckel, H. E., Kreft, M. P., Klussmann, J. P., Gudziol, H., Huttenbrink, K. B., & Hummel, T. (2004). Olfactory dysfunction - epidemiological data and treatment strategies in Germany, Austria, and Switzerland. *Hno*, *52*(2), 112-120. <u>https://doi.org/DOI</u> 10.1007/s00106-003-0877-z

Devanand, D. P., Lee, S., Manly, J., Andrews, H., Schupf, N., Masurkar, A., Stern, Y., Mayeux, R., & Doty, R. L. (2015). Olfactory identification deficits and increased mortality in the community. *Ann Neurol*, *78*(3), 401-411. <u>https://doi.org/10.1002/ana.24447</u>

Doty, R. L., Shaman, P., Kimmelman, C. P., & Dann, M. S. (1984). University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. *Laryngoscope*, *94*(2 Pt 1), 176-178.

Drydak, R., & Albert, J. (2021). Utredning av den initiala smittspridningen av SARS-CoV-2 till och inom Sverige.

Gerkin, R. C., Ohla, K., Veldhuizen, M. G., Joseph, P. V., Kelly, C. E., Bakke, A. J., Steele, K. E., Farruggia, M. C., Pellegrino, R., Pepino, M. Y., Bouysset, C., Soler, G. M., Pereda-Loth, V., Dibattista, M., Cooper, K. W., Croijmans, I., Di Pizio, A., Ozdener, M. H., Fjaeldstad, A. W., . . . Author, G. G. (2021). Recent Smell Loss Is the Best Predictor of COVID-19 Among

It is made available under a CC-BY-NC-ND 4.0 International license .

Individuals With Recent Respiratory Symptoms. *Chem Senses*, 46. <u>https://doi.org/10.1093/chemse/bjaa081</u>

Hopkins, C., Surda, P., Vaira, L. A., Lechien, J. R., Safarian, M., Saussez, S., & Kumar, N. (2021). Six month follow-up of self-reported loss of smell during the COVID-19 pandemic. *Rhinology*, *59*(1), 26-31. <u>https://doi.org/10.4193/Rhin20.544</u>

Hummel, T., Sekinger, B., Wolf, S. R., Pauli, E., & Kobal, G. (1997). "Sniffin' sticks": olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. *Chem Senses*, *22*, 39-52.

Hummel, T., Whitcroft, K. L., Andrews, P., Altundag, A., Cinghi, C., Costanzo, R. M., Damm, M., Frasnelli, J., Gudziol, H., Gupta, N., Haehne, A., Holbrook, E., Hong, S. C., Hornung, D., Huttenbrink, K. B., Kamel, R., Kobayashi, M., Konstantinidis, I., Landis, B. N., . . . Welge-Luessen, A. (2017). Position paper on olfactory dysfunction. *Rhinol Suppl*, *54*(26), 1-30. <u>https://doi.org/10.4193/Rhino16.248</u>

Karpa, M. J., Gopinath, B., Rochtchina, E., Jie Jin, W., Cumming, R. G., Sue, C. M., & Mitchell, P. (2010). Prevalence and neurodegenerative or other associations with olfactory impairment in an older community. *J Aging Health*, *22*(2), 154-168. <u>https://doi.org/10.1177/0898264309353066</u>

Konstantinidis, I., Haehner, A., Frasnelli, J., Reden, J., Quante, G., Damm, M., & Hummel, T. (2006). Post-infectious olfactory dysfunction exhibits a seasonal pattern. *Rhinology*, *44*(2), 135-139.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_ui ds=16792173

Landis, B. N., Frasnelli, J., Croy, I., & Hummel, T. (2010). Evaluating the clinical usefulness of structured questions in parosmia assessment. *Laryngoscope*, *120*(8), 1707-1713. <u>https://doi.org/10.1002/lary.20955</u>

Landis, B. N., Hummel, T., Hugentobler, M., Giger, R., & Lacroix, J. S. (2003). Ratings of overall olfactory function. *Chem Senses*, *28*(8), 691-694. <u>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14627537</u>

Landis, B. N., Konnerth, C. G., & Hummel, T. (2004). A study on the frequency of olfactory dysfunction. *Laryngoscope*, *114*(10), 1764-1769. <u>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15454769</u>

Lechien, J. R., Chiesa-Estomba, C. M., Beckers, E., Mustin, V., Ducarme, M., Journe, F., Marchant, A., Jouffe, L., Barillari, M. R., Cammaroto, G., Circiu, M. P., Hans, S., & Saussez, S. (2021). Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med*, *290*(2), 451-461. <u>https://doi.org/10.1111/joim.13209</u>

Lotsch, J., & Hummel, T. (2019). Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science-Based Assessment of 6000 Patients. *Chem Senses*, *44*(6), 357-364. <u>https://doi.org/10.1093/chemse/bjz029</u>

McWilliams, M. P., Coelho, D. H., Reiter, E. R., & Costanzo, R. M. (2022). Recovery from Covid-19 smell loss: Two-years of follow up. *Am J Otolaryngol*, *43*(5), 103607. https://doi.org/10.1016/j.amjoto.2022.103607

Nordin, S., Bramerson, A., Millqvist, E., & Bende, M. (2007). Prevalence of parosmia: the Skovde population-based studies. *Rhinology*, *45*(1), 50-53. https://www.ncbi.nlm.nih.gov/pubmed/17432070

Ohla, K., Veldhuizen, M. G., Green, T., Hannum, M. E., Bakke, A. J., Moein, S. T., Tognetti, A., Postma, E. M., Pellegrino, R., Hwang, D. L. D., Albayay, J., Koyama, S., Nolden, A.

A., Thomas-Danguin, T., Mucignat-Caretta, C., Menger, N. S., Croijmans, I., Ozturk, L., Yanik, H., . . . Niv, M. Y. (2022). A follow-up on quantitative and qualitative olfactory dysfunction and other symptoms in patients recovering from COVID-19 smell loss. *Rhinology*, 10.4193/Rhin21.41. https://doi.org/10.4193/Rhin21.415

Oleszkiewicz, A., Schriever, V. A., Croy, I., Hahner, A., & Hummel, T. (2019). Updated Sniffin' Sticks normative data based on an extended sample of 9139 subjects. *Eur Arch Otorhinolaryngol*, *276*(3), 719-728. <u>https://doi.org/10.1007/s00405-018-5248-1</u>

Olofsson JK, Ekesten F, Nordin S. Olfactory distortions in the general population. Sci Rep. 2022 Jun 13;12(1):9776. doi: 10.1038/s41598-022-13201-5.

Parma, V., Ohla, K., Veldhuizen, M. G., Niv, M. Y., Kelly, C. E., Bakke, A. J., Cooper, K. W., Bouysset, C., Pirastu, N., Dibattista, M., Kaur, R., Liuzza, M. T., Pepino, M. Y., Schopf, V., Pereda-Loth, V., Olsson, S. B., Gerkin, R. C., Rohlfs Dominguez, P., Albayay, J., . . . Hayes, J. E. (2020). More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. *Chem Senses*, *45*(7), 609-622.

Pin, E., Sjoberg, R., Andersson, E., Hellstrom, C., Olofsson, J., Jernbom Falk, A., Bergstrom, S., Remnestal, J., Just, D., Nilsson, P., & Manberg, A. (2019). Array-Based Profiling of Proteins and Autoantibody Repertoires in CSF. *Methods Mol Biol*, *2044*, 303-318. <u>https://doi.org/10.1007/978-1-4939-9706-0_19</u>

Reden, J., Mueller, A., Mueller, C., Konstantinidis, I., Frasnelli, J., Landis, B. N., & Hummel, T. (2006). Recovery of olfactory function following closed head injury or infections of the upper respiratory tract. *Arch Otolaryngol Head Neck Surg*, *13*2(3), 265-269. https://doi.org/132/3/265 [pii]

10.1001/archotol.132.3.265

Rudberg, A. S., Havervall, S., Manberg, A., Jernbom Falk, A., Aguilera, K., Ng, H., Gabrielsson, L., Salomonsson, A. C., Hanke, L., Murrell, B., McInerney, G., Olofsson, J., Andersson, E., Hellstrom, C., Bayati, S., Bergstrom, S., Pin, E., Sjoberg, R., Tegel, H., . . . Thalin, C. (2020). SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nat Commun*, *11*(1), 5064. <u>https://doi.org/10.1038/s41467-020-18848-0</u>

Seiden, A. M. (2004). Postviral olfactory loss. *Otolaryngol Clin North Am*, 37(6), 1159-1166. <u>https://doi.org/10.1016/j.otc.2004.06.007</u>

Vihta, K. D., Pouwels, K. B., Peto, T. E., Pritchard, E., House, T., Studley, R., Rourke, E., Cook, D., Diamond, I., Crook, D., Clifton, D. A., Matthews, P. C., Stoesser, N., Eyre, D. W., Walker, A. S., & team, C.-I. S. (2022). Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. *Clin Infect Dis*. <u>https://doi.org/10.1093/cid/ciac613</u>

Xydakis, M. S., Albers, M. W., Holbrook, E. H., Lyon, D. M., Shih, R. Y., Frasnelli, J. A., Pagenstecher, A., Kupke, A., Enquist, L. W., & Perlman, S. (2021). Post-viral effects of COVID-19 in the olfactory system and their implications. *Lancet Neurol*, *20*(9), 753-761. <u>https://doi.org/10.1016/s1474-4422(21)00182-4</u>